dapi has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies
DAPI: RN given refers to parent cpd.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Skundric, DS | 1 |
| Dai, R | 1 |
| Zakarian, VL | 1 |
| Bessert, D | 1 |
| Skoff, RP | 1 |
| Cruikshank, WW | 1 |
| Kurjakovic, Z | 1 |
1 other study available for dapi and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Topics: Animals; Antibodies; B-Lymphocytes; Blotting, Western; CD4 Antigens; CD4-Positive T-Lymphocytes; Dis | 2005 |